A second market research report has found evidence that production
capacity in the market for contract manufacturing of
biopharmaceuticals is now in excess, in contrast to the hitherto
prevailing wisdom that the sector has been suffering...
Hamilton Life Science Robotics has taken Invitrogen's Gateway
Technology one step further by creating an automated cloning system
that monitors and tracks each plate undergoing various processes.
The system aims to further refine...
Boehringer Ingelheim Austria has been selected to win a Technology
Leadership award by Frost & Sullivan for its activities in the
contract manufacture of biotherapeutic proteins, and particularly
Genetix Limited has launched the ClonePixFL, a mammalian cell
imaging and picking instrument that builds upon the success of the
ClonePix adding fluorescent capabilities to its clone picking
Construction of the UK National Biomanufacturing Centre, an
ambitious project aimed at helping biotechnology start-ups get
their product ideas into clinical trials, is progressing on
schedule and should be ready to start production...
Despite burgeoning demand for biopharmaceutical drugs, little
progress is being made toward the improving efficiency and reducing
costs in conventional biomanufacturing processes using microbial or
mammalian fermentation systems.
US chemicals company Aceto has broken cover and is now racing to
develop a leading player in the market for generic versions of
biologic drugs, even though the regulatory route to approval of
these products is far from established.
Qiagen has announced a new product line for the separation,
purification and handling of nucleic acids, an essential process in
drug discovery, which aims to improve over current applied methods,
which suffer from decreased sensitivity...
The predicted deficit in manufacturing capacity for biologic drugs
that has been tipped to impede the development of the market has
not materialised, with capacity exceeding demand, according to new
Switzerland-based BioPartners has submitted a second Marketing
Authorisation Application in Europe for a generic copy of a
biologic drug under the recently agreed European Union framework
for so-called 'biosimilar' drugs.